Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study.
BACKGROUND
Cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improves the overall survival in selected cases of peritoneal carcinomatosis (PC) of colorectal origin. Second-look surgery in asymptomatic patients at high risk of developing PC has shown encouraging results. This study aims at identifying cases in which initial anastomosis should be resected.


METHODS
Patients treated by second-look surgery and HIPEC were identified from a prospective database. High-risk was defined as synchronous resected and minimal PC, ovarian metastasis or perforated primary tumor. Patients were divided in two groups based on intra-operative evaluation of the anastomosis: possibly-invaded (PI) and unlikely-invaded (UI). PI was defined as 1) PC away from the anastomosis, 2) nodules resting on the anastomosis 3) anastomotic stenosis or anastomotic thickening. Anastomosis in the PI group were resected.


RESULTS
Forty patients were included: 12 in the PI group and 28 in the UI group. Incidence of pathological anastomotic invasion was 42% (5 on 12 patients) in the PI group. In the UI group, 2 patients had anastomotic recurrence, both associated with peritoneal recurrence. Morbidity and mortality was not influenced by anastomosis resection. The presence of suspicious nodules on the anastomosis had a sensitivity of 100% and a specificity of 89% in predicting anastomotic invasion.


CONCLUSIONS
In second-look surgery and HIPEC for colorectal cancer at high-risk of PC, anastomosis should be resected when overlying PC nodules are found. This attitude is supported by high sensitivity of this finding for anastomotic invasion and low morbidity related to anastomotic resection.
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France. Electronic address: alexiscloutier@gmail.com.
A S
AS
Cloutier
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
M
M
Faron
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
C
C
Honoré
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
D
D
Goéré
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
F
F
Dumont
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
F
F
Vittadello
Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Grand Paris, France.
D
D
Élias
D000714:Anastomosis, Surgical / Q000379:methods; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003106:Colon / Q000601:surgery*; D015179:Colorectal Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D010534:Peritoneal Neoplasms / Q000628:therapy*; D012007:Rectum / Q000601:surgery*; D012189:Retrospective Studies; D024162:Second-Look Surgery / Q000379:methods*; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Colorectal anastomosis; Colorectal cancer; Peritoneal cancer index; Peritoneal metastases; Second-look surgery